Cytokines and Co-stimulation in Acute Graft-versus-Host Disease.

Like Comment
Allogeneic hematopoietic stem cell transplantation (alloSCT) is an important curative therapy for high-risk hematological malignancies, but the development of severe and/or steroid-refractory acute graft-versus-host disease (aGVHD) remains a significant limitation to optimal outcomes. New approaches to prevent and treat aGVHD remain an unmet need that can be best addressed by understanding the complex disease pathophysiology. It is now clear that chemoradiotherapy utilized prior to alloSCT induces the release of endogenous alarmins (e.g. HMGB-1, ATP, IL-1α, IL-33) from recipient tissue. Exogenous pathogen-derived molecules (e.g. LPS, nucleic acids) also translocate from the gastrointestinal tract lumen. Together, these danger signals activate antigen presenting cells (APC) to efficiently present alloantigen to donor T cells whilst releasing cytokines (e.g. IL-12, IL-23, IL-6, IL-27, IL-10, TGFb) that expand and differentiate both pathogenic and regulatory donor T cells. Concurrent co-stimulatory signals at the APC-T cell interface (e.g. CD80/CD86-CD28, CD40-CD40L, OX40L-OX40, CD155/CD112-DNAM-1) and subsequent co-inhibitory signals (e.g. CD80/CD86-CTLA4, PDL1/2-PD1, CD155/CD112-TIGIT) are critical to the acquisition of effector T cell function and ensuing secretion of pathogenic cytokines (e.g. IL-17, IFNg, TNF, GM-CSF) and cytolytic degranulation pathway effectors (e.g. perforin/granzyme). This review focuses on the combination of cytokine and costimulatory networks at the T cell surface that culminates in effector function and subsequent aGVHD in target tissue. Together, these pathways now represent robust and clinically tractable targets for preventing the initiation of deleterious immunity after alloSCT.


Click here to read the full article @ Blood

ClinOwl

The wider, wiser view for healthcare professionals. ClinOwl signposts the latest clinical content from over 100 leading medical journals.
3882 Contributions
1 Followers
0 Following

No comments yet.